These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4438990)

  • 61. Treatment of primary hyperlipoproteinaemias with a tetralin derivative (Su-13'437).
    Fellin R; Fedele D; Bagnariol G; Pagnan A; Crepaldi G
    Atherosclerosis; 1973; 17(3):383-8. PubMed ID: 4577009
    [No Abstract]   [Full Text] [Related]  

  • 62. [Hypolipidemic action of simfibrate in diabetic subjects].
    Gragnoli G; Tanganelli I; Signorini AM; Kristodhullu A
    Clin Ter; 1981 Feb; 96(4):397-408. PubMed ID: 7214862
    [No Abstract]   [Full Text] [Related]  

  • 63. [Coenzyme A and dyslipidemia. Note I. Rapid changes in lipid and lipoprotein levels induced with coenzyme A in humans].
    Consolo F; Di Tommaso G; Arrigo F; Trifirò A
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1920-6. PubMed ID: 1231873
    [No Abstract]   [Full Text] [Related]  

  • 64. [Clinical study on the relationship between diabetes, hyperlipoproteinemia and atheromatosis].
    Righetti A; Scherrer JR; Micheli H; Pometta D
    Schweiz Med Wochenschr; 1973 May; 103(18):668-73. PubMed ID: 4702987
    [No Abstract]   [Full Text] [Related]  

  • 65. [Systematic study of a median tolerance to a high-fat test diet in hyperlipemia or hyperglyceridemia].
    de Gennes JL; Truffert J; Salmon D; de Tregomain B; Bouchon JP
    Ann Med Interne (Paris); 1969 Dec; 120(12):787-802. PubMed ID: 5377660
    [No Abstract]   [Full Text] [Related]  

  • 66. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050
    [No Abstract]   [Full Text] [Related]  

  • 67. [Clinical evaluation of the antidyslipemic action of a sulfomucopolysaccharide of pancreatic origin].
    Svetoni N; D'Alonzo D; Rechichi A
    Clin Ter; 1974 Oct; 71(1):33-48. PubMed ID: 4279159
    [No Abstract]   [Full Text] [Related]  

  • 68. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
    Fodor JG; Frohlich JJ; Genest JJ; McPherson PR
    CMAJ; 2000 May; 162(10):1441-7. PubMed ID: 10834048
    [No Abstract]   [Full Text] [Related]  

  • 69. [Acipimox treatment of hyperlipidemia type II].
    Noseda G; Fragiacomo C; Cairoli R
    Schweiz Med Wochenschr; 1982 Dec; 112(49):1790-1. PubMed ID: 6758114
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hyperlipidemia.
    Sloan RW
    Am Fam Physician; 1983 Sep; 28(3):171-82. PubMed ID: 6613796
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    McCrindle BW; Ose L; Marais AD
    J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
    Espinosa RA; Rodríguez-Roa E; Nagy E; Mijares ME; Rodríguez-Larralde A; Gil A; Lundberg U; Carvajal Z; Castillo L; Arocha-Piñango CL
    Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Management of common forms of hyperlipidaemia.
    Nestel PJ
    Aust Fam Physician; 1985 Aug; 14(8):798, 800, 802. PubMed ID: 4051899
    [No Abstract]   [Full Text] [Related]  

  • 74. [Long-term administration of tyquanol in the treatment of patients with ischemic heart disease in combination with hyperlipidemia].
    Panchenko VM; Ershov AA; Isaev VA
    Klin Med (Mosk); 2003; 81(3):40-2. PubMed ID: 12698850
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR
    Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Clinical valuation of "Plasmaclar", a new drug for the treatment of hyperlipaemias (author's transl)].
    Ferrer García JL
    Folia Clin Int (Barc); 1973 Nov; 23(11):782-94. PubMed ID: 4773216
    [No Abstract]   [Full Text] [Related]  

  • 77. Classification and etiology of hyperlipoproteinemias.
    Levy RI
    Fed Proc; 1971; 30(3):829-34. PubMed ID: 5575295
    [No Abstract]   [Full Text] [Related]  

  • 78. Editorial: Is control of hyperlipidaemia important in renal diseases?
    Med J Aust; 1974 Jul; 2(4):115-8. PubMed ID: 4608833
    [No Abstract]   [Full Text] [Related]  

  • 79. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Effects of glucuronyl-glucosamino-glycan sulfate in a group of patients with blood lipid disorders].
    Cossu G
    Clin Ter; 1979 Jan; 88(2):173-81. PubMed ID: 428197
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.